GOSS Overview

Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Wall Street analysts forecast GOSS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOSS is12.33 USD with a low forecast of 10.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Gossamer Bio Inc revenue for the last quarter amounts to 13.80M USD, increased 47.13

Gossamer Bio Inc. EPS for the last quarter amounts to -0.20 USD, increased 33.33

Gossamer Bio Inc (GOSS) has 161 emplpoyees as of April 10 2026.

Today GOSS has the market capitalization of 87.21M USD.